Clinical Trials
178 trialsLetrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
NSABP Foundation Inc
PATHWAY
National Cancer Center, Japan
A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
RemeGen Co., Ltd.
Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial)
Seoul National University Hospital
ASF-BC
Uppsala University Hospital
CLOVER
Fudan University
Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.
Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)
Guangdong Provincial People's Hospital
SRSvsWBRT
Post Graduate Institute of Medical Education and Research, Chandigarh
FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
Betta Pharmaceuticals Co., Ltd.
HOT
European Institute of Oncology
A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
ANGLeD
Angiochem Inc
Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy
Blau Farmaceutica S.A.
HOBOE
National Cancer Institute, Naples
A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)
CSPC Ouyi Pharmaceutical Co., Ltd.
CONTROL
Humanitas Hospital, Italy
Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms
Cairo University
ASPAIT
First Affiliated Hospital, Sun Yat-Sen University
Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients
Mansoura University
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
STARS
Trans Tasman Radiation Oncology Group
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Ahon Pharmaceutical Co., Ltd.
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Ahon Pharmaceutical Co., Ltd.
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
DEDiCa
National Cancer Institute, Naples
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
Fudan University
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
NSABP Foundation Inc
Tranexamic Acid for Alloplastic Breast Reconstruction
McMaster University
SAFE
Azienda Ospedaliero-Universitaria Careggi
Radiation Dose Intensity Study in Breast Cancer in Young Women
The Netherlands Cancer Institute
Radiotherapy for Extracranial Oligometastatic Breast Cancer
ChineseAMS
Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole
Assiut University
Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy
Peking University
Accuracy of VABB Elite 10G Versus BARD 14G CNB
Fudan University
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.
Kafrelsheikh University
Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer
Shengjing Hospital
Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer
Taizhou EOC Pharma Co., Ltd.
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Radiation Therapy for ypN0 Breast Cancer
National Cancer Institute, Egypt
Elective Internal Mammary Node Irradiation in Women With Node-positive Breast Cancer
Yonsei University
Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer
Zhejiang Cancer Hospital
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Jiangsu HengRui Medicine Co., Ltd.
CAMELLIA
ChineseAMS